A PROSPECTIVE PHASE II, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF SEG101 (CRIZANLIZUMAB) IN SICKLE CELL DISEASE PATIENTS WITH PRIAPISM (SPARTAN)

被引:1
|
作者
Burnett, A. [1 ]
El Rassi, F. [2 ]
Darbari, D. [3 ]
Paulose, J. [4 ]
Laine, D. [4 ]
Purkayastha, D. [4 ]
Kato, G. [5 ]
机构
[1] Johns Hopkins Sch Med, Baltimore, MD USA
[2] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[3] Childrens Natl Med Ctr, Washington, DC 20010 USA
[4] Novartis Pharmaceut, Basel, Switzerland
[5] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA
来源
JOURNAL OF SEXUAL MEDICINE | 2020年 / 17卷 / 01期
关键词
D O I
10.1016/j.jsxm.2019.11.092
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
147
引用
收藏
页码:S43 / S43
页数:1
相关论文
共 50 条
  • [21] Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)
    Okada, Morihito
    Kijima, Takashi
    Aoe, Keisuke
    Kato, Terufumi
    Fujimoto, Nobukazu
    Nakagawa, Kazuhiko
    Takeda, Yuichiro
    Hida, Toyoaki
    Kanai, Kuninobu
    Imamura, Fumio
    Oizumi, Satoshi
    Takahashi, Toshiaki
    Takenoyama, Mitsuhiro
    Tanaka, Hiroshi
    Hirano, Jun
    Namba, Yoshinobu
    Ohe, Yuichiro
    CLINICAL CANCER RESEARCH, 2019, 25 (18) : 5485 - 5492
  • [22] Efficacy and safety of sirolimus treatment for intractable lymphatic anomalies: A study protocol for an open-label, single-arm, multicenter, prospective study (SILA)
    Ozeki, Michio
    Asada, Ryuta
    Saito, Akiko M.
    Hashimoto, Hiroya
    Fujimura, Takumi
    Kuroda, Tatsuo
    Ueno, Shigeru
    Watanabe, Shoji
    Nosaka, Shunsuke
    Miyasaka, Mikiko
    Umezawa, Akihiro
    Matsuoka, Kentaro
    Maekawa, Takanobu
    Yamada, Yohei
    Fujino, Akihiro
    Hirakawa, Satoshi
    Furukawa, Taizo
    Tajiri, Tatsuro
    Kinoshita, Yoshiaki
    Souzaki, Ryota
    Fukao, Toshiyuki
    REGENERATIVE THERAPY, 2019, 10 : 84 - 91
  • [23] Phase II Open-Label, Single-Arm Trial to Investigate the Efficacy and Safety of Topical Remetinostat Gel in Patients with Basal Cell Carcinoma
    Kilgour, James M.
    Shah, Aatman
    Urman, Nicole M.
    Eichstadt, Shaundra
    Do, Hanh N.
    Bailey, Irene
    Mirza, Amar
    Li, Shufeng
    Oro, Anthony E.
    Aasi, Sumaira Z.
    Sarin, Kavita Y.
    CLINICAL CANCER RESEARCH, 2021, 27 (17) : 4717 - 4725
  • [24] Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: A multicenter, open-label, single-arm, phase II study
    Wu, X.
    Xia, L.
    Wang, J.
    Wang, C.
    Zhang, Q.
    Zhu, J.
    Rao, Q.
    Cheng, H.
    Liu, Z.
    Yin, Y.
    Ai, X.
    Gulina, K.
    Zheng, H.
    Luo, X.
    Chang, B.
    Li, L.
    Liu, H.
    Li, Y.
    Zhu, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S1506 - S1506
  • [25] EFFICACY AND SAFETY OF ZIMBERELIMAB (GLS-010) MONOTHERAPY IN PATIENTS WITH RECURRENT OR METASTATIC CERVICAL CANCER: A MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE II STUDY
    Wu, Xiaohua
    Xia, Lingfang
    Wang, Jing
    Wang, Chunyan
    Zhang, Qingming
    Zhu, Jianqing
    Rao, Qunxian
    Cheng, Huijun
    Liu, Zheng
    Yin, Yongmei
    Ai, Xiaohong
    Gulina, Kurban
    Zheng, Hong
    Luo, Xiaoyong
    Chang, Baoping
    Li, Li
    Liu, Haiyan
    Li, Yunxia
    Lou, Ge
    Zhou, Qi
    Zhu, Yanling
    Xiao, Zemin
    Tong, Jiandong
    Wang, Ke
    Chen, Jie
    Wang, Xia
    Song, Lijie
    Wei, Zhixia
    Ye, Yijing
    Zhu, Jiman
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A703 - A703
  • [26] Efficacy and safety of pantoprazole and itopride in patients with overlap of gastroesophageal reflux disease and dyspepsia: A prospective, open-label, single-arm pilot study
    Lakhtakia, Sundeep
    Singh, Aniruddha P.
    Singla, Neeraj
    Memon, Sana F.
    Reddy, Duvvur N.
    JGH OPEN, 2024, 8 (02):
  • [27] A multicenter, open-label, single-arm, phase IV study evaluating the safety of biosimilar bevacizumab in patients with solid tumors
    Narayanan, P.
    Upveja, K. H.
    Deodhar, S.
    Kapur, R.
    ANNALS OF ONCOLOGY, 2024, 35 : S1613 - S1613
  • [28] Safety and Efficacy of Apatinib Monotherapy for Unresectable, Metastatic Esophageal Cancer: A Single-Arm, Open-Label, Phase II Study
    Li Yanwei
    Feng, He
    Ren, Peng
    Yue, Jie
    Zhang, Wencheng
    Tang, Peng
    Shang, Xiaobin
    Pang, Qingsong
    Liu, Dongying
    Chen, Chuangui
    Pan, Zhanyu
    Tao, Yu Zhen
    ONCOLOGIST, 2020, 25 (10): : E1464 - E1472
  • [29] Pharmacokinetics/Pharmacodynamics, Safety and Efficacy of Crizanlizumab in Patients with Sickle Cell Disease and a History of Vaso-Occlusive Crises: Results from the Phase II, Multicenter, Open-Label Solace-Adults Study
    Liles, Darla
    Smith-Whitley, Kim
    Brown, R. Clark
    Shah, Nirmish
    Nair, Santosh M.
    Tanaka, Chiaki
    Bodla, Shankaranand
    Sanchez-Olle, Gessami
    Albers, Urs
    Kanter, Julie
    BLOOD, 2020, 136
  • [30] An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia
    Patton, William Nigel
    Lindeman, Robert
    Butler, Andrew C.
    Kipps, Thomas J.
    Jewell, Roxanne C.
    Laubscher, Kevin H.
    Zhou, Yan Yan
    Lewis, Eric
    Sedoti, Donna
    Witman, Philip
    Fang, Lei
    Chan, Geoffrey
    LEUKEMIA & LYMPHOMA, 2015, 56 (10) : 2819 - 2825